Resident microbes shape host immunity and protect against pathogen infection and inflammatory disease Authors: Daichi Mori, Yoshiyuki Goto Published: 2026 ABSTRACT AbstractThe gastrointestinal tract harbors a vast and diverse community of microorganisms that establish a mutualistic and stable relationship with the host. These resident microbes play critical roles in protecting the host from luminal antigens, particularly pathogenic and opportunistic microorganisms, while simultaneously contributing to intestinal homeostasis. Accumulating evidence indicates that the gut microbiota profoundly shapes the development, differentiation, and function of epithelial and immune cells through coordinated molecular and cellular interactions. Recent studies have highlighted that barrier formation and immune homeostasis in the intestine are not solely host-driven processes but rather arise from cooperative interactions between resident microorganisms and host epithelial and immune compartments. Microbiota-derived signals promote epithelial integrity and instruct innate and adaptive immune responses, collectively establishing a robust yet tightly regulated infection-defense system that suppresses intestinal inflammation and maintains immune homeostasis. In this review, we focus on the role of the gut microbiota in the development of the host immune system, especially innate and adaptive lymphocytes, including epithelial cells, innate lymphoid cells, Th17 cells, and IgA+ B cells. We discuss how resident microorganisms shape these immune components to form a protective barrier system that not only confers resistance to pathogenic and opportunistic microbial infections but also maintains local and systemic immune homeostasis. Furthermore, we address how disruption of these microbiota-driven regulatory networks can contribute to the development of inflammatory diseases, highlighting the importance of host–microbiota interactions in health and disease.Keywords: Microbiota, Colonization resistance, IECs, Th17, ILC3, IgA Introduction A myriad of microorganisms symbiotically reside in the gastrointestinal tract. Commensal microbes, including bacteria, fungi, parasites, and viruses, have pleiotropic functions and help regulate the host’s pathophysiological state. These microorganisms play essential roles in maintaining homeostasis within the gastrointestinal microenvironment. A pivotal role of the gut bacteria is to inhibit colonization of pathogenic and non-pathogenic microbes in the intestine. This effect is conserved across the various kingdoms of living organisms from lower animals to humans. Disruption of the microbiota, namely dysbiosis, caused by antibiotic use or limited nutrient intake, or the complete absence of gut bacteria, such as in germ-free mice, allows for the growth of pathogens such as Listeria monocytogenes, Salmonella Typhimurium, and Citrobacter rodentium in the gut [1–3]. In addition, the gut microbiota prevents the growth and colonization of opportunistic microbes such as Clostridioides difficile, vancomycin-resistant Enterococcus, and Candida albicans [4–6]. Therefore, disruption of the microbiota facilitates the invasion of opportunistic pathogens, leading to infections in immunocompromised individuals. Notably, colonization resistance is not achieved by a single member of the microbiota; instead, multiple bacterial species participate in and form an interaction network that establishes an antimicrobial barrier system. In response to signals from the dynamic intestinal microenvironment, resident microbes adapt their metabolism, physiology, and gene expression to optimize survival within this niche. In addition, microbiomes are tightly regulated by the host genetic background, developmental stage, and physiology, including immune signatures. Therefore, the formation of the microbiota is influenced by complex environmental and host-derived factors. Although regulating the microbiome is challenging, various approaches, including fecal microbiota transplantation, nutritional interventions, pre- and probiotic treatments, and phage therapies, are being evaluated for the treatment of multiple diseases. Several mechanisms have been reported by which commensal bacteria prevent colonization by pathogenic and opportunistic microbes. A combination of three critical functions of resident microbes, namely (1) competitive domination of the environmental niche, (2) production of antimicrobial molecules, and (3) induction of host immune responses, forms a pleiotropic and multi-layered antimicrobial defense system in the intestine. Various environmental factors, including nutrients, drugs, pH, humidity, and oxygen concentration, affect the survival, proliferation, and colonization of microbes in the gastrointestinal tract. Resident gut microbes competitively occupy this niche and inhibit the proliferation and colonization of pathogenic and opportunistic microbes. For example, resident bacteria consume oxygen that is critical for the growth of aerobic pathogens. Resident bacteria also produce a variety of metabolites, including short-chain fatty acids (SCFAs), organic acids, secondary bile acids, vitamins, and indole derivatives [7–10]. SCFAs and lactate maintain an acidic intestinal pH, thereby preventing pathogen proliferation. Bacteriocins are important antimicrobial molecules produced by resident bacteria. For example, ubiquitous lactic acid bacteria in mammals, such as Lactobacillus reuteri, produce reuterin, a broad-spectrum antimicrobial compound that suppresses a wide range of pathogenic microorganisms [11]. Details of these direct influences by resident microbes on pathogens are summarized in several other reviews [7, 12–14]. In addition to direct inhibitory effects, resident microbes stimulate host epithelial and immune responses that contribute to pathogen eradication. Immune cells constitutively detect signals from luminal resident microbes via receptors for microbe-associated molecular patterns, such as lipopolysaccharide, peptidoglycan, and CpG DNA. These bioactive molecules are detected by pattern recognition receptors, such as toll-like receptors (TLRs), Nod-like receptors (NLRs), and RIG-I-like receptors, which modulate the surface barrier system established by epithelial cells and by innate and acquired immune cells. For example, TLR2/4 signaling mediates MyD88-induced epithelial growth and the production of antimicrobial molecules such as RegIIIβ/γ [5, 15]. In addition to microbe-associated molecular patterns, bacterial metabolites, such as SCFAs, modulate immune cells, including regulatory T (Treg) cells, thereby regulating intestinal homeostasis [16]. Upon recognition of these microbe-derived molecules, host epithelial and immune cells are sequentially activated. A combination of microbial stimuli and antigens in dendritic cells activates, proliferates, and differentiates T and B cells, thereby maturing secondary lymphoid organs in the gut. Importantly, this succession of signals from resident microorganisms highlights the unique features of the gut immune system and creates a barrier system against external pathogenic and opportunistic microbes. In this review, we discuss how intestinal microorganisms influence the development of host immune cells. We also review the mechanisms by which immune cells induced by commensal microorganisms protect against infection and inflammation and discuss approaches to limit these infections in an era of increasing antibiotic resistance. Bidirectional crosstalk between intestinal epithelial cells, the microbiota, and host immunity establishes a barrier against enteric pathogens As described above, the unique characteristics of the gut epithelial and immune systems are shaped by multiple factors, among which the gut microbiota, continuously colonizing the intestinal lumen, plays a central role. In addition to nutrients from the host’s daily diet, the habitat, homeostasis, and function of these microorganisms are regulated by mucus and antimicrobial molecules produced by the host’s epithelial cells. In this context, we discuss columnar epithelial cells, Paneth cells, and goblet cells, which collectively form a physical, chemical, and immunological barrier and are particularly important for regulating gut-resident and pathogenic microbes. The primary cells comprising the intestinal epithelial layer are columnar epithelial cells, which function as the first line of defense against luminal antigens. Epithelial cells, closely attached via tight junctions, play an essential role in separating the host from the gut luminal environment [17]. Indeed, mice deficient in claudin (claudin-2), a protein critical for tight junctions, show delayed clearance of C. rodentium and more severe colonic mucosal damage [18]. The columnar epithelial cells also produce various antimicrobial molecules to prevent colonization and invasion of luminal microbes. For example, as described below, regenerating family member III (RegIII) is a critical antimicrobial lectin produced by epithelial cells of the small and large intestine that prevents pathogenic bacterial infection [5, 19]. In addition, Lypd8, produced by colonic epithelial cells, reduces bacterial motility by binding to bacterial flagella, thereby preventing their entry into the mucus surrounding intestinal epithelial cells; Lypd8-deficient mice (Lypd8˗/˗) are highly susceptible to ulcerative colitis [20]. Thus, intestinal epithelial cells not only constitute the first line of host defense but also possess bacterial selectivity. It has become evident that the establishment of this highly sophisticated defense system requires a tightly regulated environmental niche. Paneth cells Paneth cells are located in the crypts of the villi of the small intestine. These cells secrete several antimicrobial peptides (AMPs) that are necessary for regulating intestinal bacteria and maintaining homeostasis in the intestinal lumen [21]. Paneth cells are located between stem cells and leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5)-positive crypt-base columnar cells [22]. AMPs derived from Paneth cells include lysozyme, secretory phospholipase A2 (sPLA2), RegIIIγ, and α-defensin [23–25]. Lysozyme is a glycosidase that is effective against gram-positive bacteria [23]. The cell wall of Staphylococcus aureus, which induces host inflammation, is composed of peptidoglycan. Lysozyme degrades this peptidoglycan, leading to interleukin (IL)−1β production by phagocytes and activation of the NLRP3 inflammasome [24]. sPLA2 expressed in Paneth cells contributes not only to prostaglandin synthesis and to the promotion of Wnt signaling during inflammation, but also to niche maintenance by assisting Lgr5+ intestinal stem cells [25]. RegIIIγ is an AMP secreted by Paneth cells as well as columnar epithelial cells and plays an essential role in regulating the microbiota. IL-22 produced by immune cells and the TLR–Myd88 axis in epithelial cells induce RegIIIγ production in Paneth cells [26, 27]. Indeed, intestinal epithelial cell-specific Myd88-deficient mice show reduced levels of mucus, which physically shields the epithelium from the microbiota, due to a reduction in RegIIIγ [19]. In addition, Myd88-deficient mice are highly susceptible to L. monocytogenes due to the loss of RegIIIγ [28]. Furthermore, Muc2˗/˗ mice have a higher mortality rate and higher numbers of pathogens in the intestinal tract and other organs than wild-type mice following infection with L. monocytogenes, a gram-positive foodborne pathogen [28]. In contrast to their beneficial and protective roles, the overproduction of AMPs may exacerbate inflammation by reducing the abundance of protective bacterial species. Enterococcus faecium produces the DL-endopeptidase SagA, which increases the rate of IL-22-producing CD4+ T cells by inducing NOD2 and IL-1β. Overproduction of RegIIIγ can aggravate enteritis by decreasing the proportion of E. faecium [29]. Therefore, optimal production of AMPs by resident bacteria contributes to the establishment of a protective barrier system against pathogen infection and to the maintenance of intestinal homeostasis. Goblet cells Although host defense is a major focus in studies of the interaction between the intestinal microbiota and intestinal epithelial cells, certain subsets of intestinal epithelial cells, including goblet cells, also play an important role in regulating the immune system. In addition, goblet cells are a unique epithelial subset critical for maintaining homeostasis between intestinal bacteria and the host [30]. Goblet cells are present throughout the intestinal tract, particularly in the large intestine, and contribute to the defense against infection by producing mucin. Muc2 is a key glycoprotein for mucin production by goblet cells; after secretion by goblet cells, it forms a polymer structure and a mucus layer covering intestinal epithelial cells [31, 32]. Mucus contributes to establishing a critical barrier against luminal microbes and preventing undesired antigen invasion and subsequent inflammation. Indeed, Muc2-deficient mice (Muc2˗/˗) are highly susceptible to dextran sulfate sodium (DSS)-induced colitis [32]. In addition to Muc2, zymogen granule protein 16 (ZG16), a mucin component, is a lectin-like protein that binds to, and forms aggregates with, the peptidoglycans of gram-positive bacteria [33]. Although the loss of ZG16 does not alter the thickness of the mucus layer, epithelial cells and bacteria are located in closer proximity in ZG16-deficient mice (ZG16˗/˗) than in wild-type mice, suggesting that ZG16 limits bacterial translocation and motility [33]. Although intestinal villous epithelial cells constitute a critical component of the host barrier against foreign antigens, including pathogens and commensal microbiota, accumulating evidence highlights their pivotal role in initiating and shaping host immune responses. For example, goblet cells transport intestinal signals to innate immune cells via goblet cell-associated antigen passages (GAPs) [30, 34]. GAPs in the intestinal tract are induced by neurotransmitters, including acetylcholine, and transport antigens to mononuclear phagocytes (MNPs), thereby activating the acquired immune system and promoting tolerance in the lumen [30, 35, 36]. This promotion of tolerance is mediated by the retinoic acid activity of IL-10-producing macrophages and dendritic cells [36]. S. Typhimurium induces the expression of Myd88 and epidermal growth factor receptor (EGFR) on goblet cells and suppresses GAPs [37]. GAPs and goblet cells are essential for translocating S. Typhimurium to the mesenteric lymph nodes, and loss of Myd88 and EGFR in goblet cells (Myd88Math1Δ and EGFRMath1Δ) and streptomycin-induced colonic GAPs increase susceptibility to S. Typhimurium. This report suggests that Myd88 and EGFR in goblet cells play an important role in preventing excessive immune responses by suppressing S. Typhimurium translocation [37]. The importance of GAPs is further supported by the reported association between late-onset neonatal sepsis and GAPs. Escherichia coli residing in the intestinal tract is a major causative agent of late-onset neonatal sepsis, which is associated with the translocation of enteric bacteria by colonic GAPs [38]. Interestingly, maternal EGF suppresses neonatal GAPs and inhibits bacterial translocation and diffusion, suggesting that GAPs influence late-onset sepsis suppression [38]. In addition to this mechanism, intestinal epithelial cells actively regulate immune cell positioning through chemokine signaling. Intestinal epithelial cells express the membrane-bound chemokine CX3CL1 (fractalkine), which contributes to the localization of CX3CR1⁺ MNPs in the intestinal mucosa [39, 40]. Indeed, CX3CL1-deficient mice (CX3CL ˗/˗) exhibit a reduced number of CX3CR1⁺CD11c⁺MHC class II⁺ cells in the intestine compared with wild-type mice [41]. The CX3CL1–CX3CR1 signaling axis further facilitates the extension of transepithelial dendrites by MNPs between epithelial cells into the lumen, enabling the direct sampling of luminal antigens and bacteria [42]. Collectively, these findings establish the concept that epithelial cells are dynamic immune sentinels that actively initiate and shape mucosal immune responses, thereby playing a central role in establishing the foundation for host defense against infection. Mechanisms of Th17 induction by the microbiota and Th17 infection defense Compared with wild-type mice, germ-free mice exhibit underdeveloped secondary lymphoid organs, including Peyer’s patches (PPs), isolated lymphoid follicles, and mesenteric lymph nodes. These secondary lymphoid organs are sites at which innate and adaptive immune cells, including B cells, T cells, and dendritic cells, accumulate. Given their importance as sites for immune responses to foreign antigens, it is conceivable that resident bacteria are necessary for the differentiation, proliferation, and survival of these immune cells, particularly lymphoid cells. In fact, the numbers of T and B cells are exceptionally low in secondary lymphoid tissues, such as the PPs in germ-free mice. In the intestine, numerous immune cells are present not only in secondary lymphoid tissues but also in the lamina propria, an immunocompetent tissue. In the lamina propria, antigen-stimulated differentiated T cells and plasma cells are observed; however, in germ-free mice, their numbers are significantly lower than in wild-type mice [43]. CD4+ T helper (Th) cells are crucial cells that govern immunity to various foreign antigens in the intestinal tract. Th cells are divided into several subsets based on master transcription factors and cytokines [44]. Th1 cells produce interferon-γ (IFN-γ) and use T-bet as a transcription factor, while Th2 cells produce IL-4 and IL-13 and use GATA3 as a transcription factor [44]. Treg cells mediate immune tolerance and suppress excessive immune responses, thereby inhibiting food allergies and inflammatory bowel disease in the gut. Furthermore, Treg cells express the transcription factor FOXP3 and produce IL-10 and TGF-β [44]. Th17 cells were identified in 2005 as a new subset of Th cells, following the discovery of Th1, Th2, and Treg cells [45, 46]. Th17 cells play a major role in intestinal homeostasis and are distinct from Th1 and Th2 cells in that they are negatively regulated by IL-4 and IFN-γ [45–47]. Retinoic acid receptor-related orphan receptor-γt (RORγt) has been identified as a master control gene for Th17 cells, and loss of RORγt (Rorcgfp/gfp) in mice results in the absence of Th17 cells [48, 49]. In addition to RORγt, STAT3 is required for Th17 cell differentiation and, when activated by IL-6 and IL-23, regulates RORγt expression [50]. Naïve T cells undergo differentiation following the induction of RORγt by STAT3 under the stimulation of T cell receptor (TCR) and cytokines such as IL-6, TGF-β, IL-23, and IL-21 [51]. TCR activation by MHC class II molecules in dendritic cells is involved in various T cell differentiation processes, and recent studies have shown that TCR signaling, with environmental cytokines, synergistically promotes STAT3 phosphorylation and activation in Th17 cells [52, 53]. Th17 cells predominantly produce IL-17a/f but also generate IL-22, IL-6, and granulocyte–macrophage colony-stimulating factors (GM-CSF), and recent reports have identified a subset of Th17 cells that produce IL-10 in the gut [54]. Th17 cells can be classified into two types based on their function: homeostatic Th17 cells that maintain host immune homeostasis and pathogenic Th17 cells that exacerbate severe inflammation in autoimmune diseases and infections [55]. Induction of Th17 cells by the microbiota Segmented filamentous bacteria (SFB) are representative resident bacteria primarily colonizing the ileum of mammals. SFB have the potential to induce Th17 cells, consistent with the observation that Th17 induction is higher in the ileum (Fig. 1) [3]. Induction of Th17 cells by SFB does not occur in mice lacking dendritic cell-specific MHC class II (CD11cΔMHCⅡ), suggesting that MHC class II expressed on dendritic cells and antigen presentation are essential for Th17 cell induction (Fig. 1) [56]. Furthermore, loss of intestinal CX3CR1 mononuclear phagocytes reduced SFB-specific T cells as well as Th17 differentiation, suggesting that CX3CR1 mononuclear phagocytes are also required for Th17 induction by SFB (Fig. 1) [57]. Th17 cells are stimulated to produce IL-17A by serum amyloid A (SAA) 1/2 derived from ileal epithelial cells, which are induced by SFB and IL-22 produced by group 3 innate lymphoid cells (ILC3) (Fig. 1) [58]. Loss of SAA1/2 reduces the expression of IL-17a and IL-17f, and stimulation by IL-6 and SAA induces Th17 cell differentiation independently of TGF-β [58, 59]. Moreover, wild-type strains of C. rodentium and E. coli O157 also induce Th17 cells. However, strains deficient in adhesion factors cannot induce Th17 cells, suggesting that bacterial adhesion to intestinal epithelial cells is essential for Th17 cell induction [60]. In this context, SFB from rats induces rat Th17 cells, but not mouse Th17 cells, because rat SFB fail to attach to murine ileal epithelial cells [60]. These findings suggest that strain-specific differences can alter the capacity of microbes to induce Th17 cells. By sensing microbial signals, intestinal epithelial cells produce immune-regulatory factors that drive the differentiation of homeostatic Th17 cells, as described later. A recent report detailed the adhesion system of SFB. Microbial adhesion-triggered endocytosis, initiated by SFB anchoring to intestinal epithelial cells, promotes immune responses by inducing epithelial uptake of SFB antigen [61]. Indeed, chemical inhibition of the cell division control protein 42 homolog (CDC42) also reduced Th17 cell induction by decreasing microbial adhesion-triggered endocytosis [61]. Resident microbes induce Th17 cells and prevent pathogen infection. Segmented filamentous bacteria (SFB) induce Th17 cells by CD103+ dendritic cells and CX3CR1+ mononuclear phagocyte-derived IL-6, IL-21, IL-23, and TGF-β, which are essential for Th17 cell induction. In addition, serum amyloid A (SAA) produced by intestinal epithelial cells contributes to Th17 cell induction. STAT3 and RORγt are critical for Th17 cell differentiation. Th17 cells act on intestinal epithelial cells and neutrophils by mediating the production of IL-10, IL-17, and IL-22. Neutrophils enhance the immune defense against bloodstream infections caused by Staphylococcus aureus In addition to bacteria in the gut, C. albicans, a representative intestinal commensal and opportunistic fungus, also contributes to the homeostasis of the gut immune system by inducing Th17 cells (Fig. 1) [59, 60]. Interestingly, mucosa-associated fungi not only induce Th17 cells and IL-22-producing CD4+ T cells to provide resistance to DSS-induced colitis but also regulate social behavior through IL-17R-dependent mechanisms in mice [62]. It has also been reported that the loss of CD103+ dendritic cells does not alter Th17 cell frequencies, whereas the loss of CX3CR1 mononuclear phagocytes dramatically reduces Th17 cells in mice colonized with C. albicans [63]. Furthermore, the protozoan Tritrichomonas musculis also induces Th1 and Th17 cells in a dendritic cell-dependent manner through the activation of inflammasomes and the promotion of IL-18 release [64]. An associated protist of T. musculis is detected in healthy human feces [64]. As such, the induction of Th17 cells in the mouse intestinal tract has been reported to be triggered not only by bacteria, but also by fungi and protists classified as eukaryotes. Bifidobacterium adolescentis is a key member of the human gut microbiota. In monocolonization experiments using germ-free mice, Th17 cells were induced more strongly by B. adolescentis than by SFB [65]. Th17 cells have also been shown to be induced by other human gut-derived bacterial species, including Clostridium, Bifidobacterium, Ruminococcus, and Bacteroides [60]. In addition, 3-oxoLCA, one of the secondary bile acids, inhibits Th17 cell differentiation by binding directly to RORγt, suggesting the impact of bacterial metabolites on modulating Th17 homeostasis in the intestine [66]. Protective and pathogenic functions of Th17 cells in immunity and inflammation A wide variety of intestinal microbes induce Th17 cells, whose functions are indispensable for host immune defense. For example, SFB-induced Th17 cells play a critical role in protection against C. rodentium infection [3]. In addition, C. albicans induces mucosal and systemic Th17 cells, thereby enhancing IL-17 responses of circulating neutrophils against S. aureus, but not influenza A virus (Fig. 1) [67]. Collectively, these findings indicate that Th17 cells induced by the gut microbiota are integral to both antimicrobial defense and the preservation of intestinal homeostasis. However, recent studies have highlighted that Th17 cells induced by the gut microbiota exhibit functional plasticity and may transition into inflammatory phenotypes, known as pathogenic Th17 cells, depending on the surrounding microenvironment. For example, SFB-induced Th17 cells can aggravate experimental autoimmune encephalomyelitis (EAE) [68]. In addition, L. reuteri and the members of the family Erysipelotrichaceae exacerbate EAE by inducing and activating autoreactive Th17 cells, suggesting a synergistic effect in the induction of Th17 cells by the gut microbiota and its impact on the development of autoimmune diseases [69]. In a recent report, a combined analysis of single-cell RNA sequencing and TCR repertoire sequencing under EAE induction revealed a stem cell-like TCF1+ SLAMF6+ IL-17 population [70]. This population migrates from the spleen to the intestine and serves as a reservoir; upon IL-23 signaling during autoimmune inflammation, it gives rise to GM-CSF+ IFN-γ+ Th17 cells capable of circulating to the central nervous system [70]. Recent studies indicate that inflammatory SFB-specific CD4+ T cells can infiltrate the central nervous system, where they activate microglia by producing inflammatory cytokines in response to host-derived antigens, leading to neurological damage [71]. In addition, gnotobiotic mice transplanted with microflora derived from primary sclerosing cholangitis were shown to harbor Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus gallinarum, which were responsible for inducing Th17 cells in the liver [72]. C. albicans-induced Th17 cells migrate from the intestine to the liver and exacerbate ethanol-induced liver disease [73]. This is supported by the fact that ethanol-induced hepatitis was more severe in Candida antigen-responsive TCR transgenic mice than in wild-type mice [73]. Such reports suggest that Th17 cells are not limited to intestinal homeostasis but also affect multiple organs and exhibit diverse pathophysiological functions. Therefore, the regulation of pathogenic Th17 cells induced by resident fungi is an attractive therapeutic target for Th17-induced inflammatory diseases. At present, extensive efforts are being devoted to characterizing pathogenic Th17 cells, alongside investigations into mechanisms by which these cells can be regulated. A recent report showed that SFB-specific Th17 cells, in which c-MAF acts as a transcription factor, are generated from TCF1+ progenitor Th17 cells and produce IL-10, which has anti-inflammatory effects [54]. These Th17 cells promoted IL-10 expression by CD4 T cells and intestinal macrophages [54]. Another study revealed that gut-resident Treg cells selectively produce IL-27 to suppress excessive Th17 responses within the intestine [74]. In addition to identifying factors that suppress pathogenic Th17 cells, recent studies have also focused on defining the metabolic characteristics of pathogenic Th17 cells as potential therapeutic targets. Interestingly, the glycolytic enzyme glucose-6-phosphate isomerase (GPI-1) was selectively induced by inflammatory encephalitogenic and colitogenic Th17 cells, whereas homeostatic Th17 cells relied on compensatory metabolic pathways, including the pentose phosphate pathway and mitochondrial respiration [75]. This metabolic distinction suggests that pathogenic Th17 cells exhibit a unique dependence on glycolysis, representing a potential therapeutic vulnerability. The authors suggest that inhibition of the glycolytic system by targeting GPI-1 could be a new therapeutic strategy against Th17 cell-induced autoimmune and other diseases. Thus, Th17 cells exhibit a dual nature: while they contribute to host defense against infection, their acquisition of pathogenic effector functions can exacerbate inflammatory diseases across multiple organs. Given their involvement in a wide range of pathologies, there is growing medical interest in elucidating how pathogenic Th17 cells can be selectively controlled. Gut microbiota-driven activation of ILC3 in the defense against infection In addition to adaptive immune cells such as Th17 cells, innate immune cells, including innate lymphoid cells (ILCs), also play crucial roles in host defense against pathogenic microorganisms and in the maintenance of intestinal homeostasis. In particular, ILC3s are well recognized as key contributors to infection defense, primarily through the induction of AMPs from epithelial cells and tissue repair via IL-22. In recent years, however, the functions of ILC3s have been shown to extend beyond these classical roles, with emerging evidence demonstrating their involvement in immune tolerance and the transmission of neural signals. Accordingly, ILC3s are now increasingly recognized as multitasking immune cells with diverse and context-dependent functions. In this section, we provide an overview of the multifaceted roles of ILC3s, with a particular focus on their activation and suppression, the induction of immune tolerance, and their interactions with the enteric nervous system (ENS). In general, ILCs are immune cells that lack antigen-specific receptors, such as TCRs and immunoglobulins. They are classified into three major groups: group 1 ILCs (ILC1), group 2 ILCs (ILC2), and group 3 ILCs (ILC3) [76, 77]. ILC1 produces IFN-γ via the transcription factor T-bet, ILC2 produces IL-5 and IL-13 via GATA3, and ILC3 produces IL-22 and IL-17 via RORγt [76]. Several subsets of ILC3 have been identified that play essential roles in intestinal homeostasis [78]. ILC3 is classified based on the expression of CCR6 [78]. A subset of CCR6+ ILC3 produces IL-22 and IL-17 and includes lymphoid tissue inducer cells, which are critical for the development of secondary lymphoid tissues such as PPs in the small intestine [79, 80]. Lymphoid tissue inducer-like cells are located in crypt patches and isolated lymphoid follicles and are important for maintaining lymphoid tissues [81]. A subset of T-bet+ ILC3 cells express NKp46 and are known to produce IL-22 and IFN-γ [82]. Activation and suppression of ILC3 by the microbiota ILC3 plays a pivotal role in patrolling, reinforcing, and repairing the epithelial barrier, primarily mediated by IL-22. Compared with conventional mice, the number of IL-22+ ILC3 cells is dramatically reduced in germ-free mice due to reduced IL-23 production, suggesting that the microbiota is tightly associated with ILC3 activation [83]. Similar to Th17, SFB are involved in ILC3 activation [58, 60, 84]. SFB mediate IL-22 production from ILC3 and are responsible for the secretion of SAA1/2, RegIIIg, and α1,2-fucosylation of intestinal epithelial cells (Fig. 2) [58, 84]. Loss of fucosyltransferase-2 (Fut2˗/˗), which is essential for α1,2-fucosylation of mucosal epithelial cells, increases susceptibility to S. Typhimurium and C. rodentium infection (Fig. 2) [84, 85]. Resident microbes modulate the functions of ILC3. Segmented filamentous bacteria (SFB) induce antimicrobial peptide (AMP) production and fucosylation through dendritic cell-derived IL-23-mediated IL-22 production in ILC3. Meanwhile, IL-1b from macrophages induces Treg differentiation via IL-2 production. SCFA and VIP are involved in IL-22 production by mediating the activity of receptors expressed on ILC3. MHC II on ILC3 suppresses Th17 cells. Furthermore, IL-22–epithelial cell interactions contribute to immune defense against Salmonella Typhimurium and Citrobacter rodentium infection via AMPs and a1,2-fucosylation Recent reports have shown that ILC3s stimulated by intestinal bacteria play diverse roles in maintaining the gut barrier and defense system. For example, ILC3 cells have been reported to contribute to trained immunity; mice pre-infected with C. rodentium one month earlier showed an enhanced IL-22 response of ILC3 compared with uninfected mice, suggesting that the first C. rodentium infection induced trained ILC3 [86]. These trained ILC3s undergo metabolic rewiring necessary for classical memory, including metabolic shifts from glycolysis and glutaminolysis to enhanced tricarboxylic acid cycle activity [86]. This report suggests that ILC3, an innate immune cell type that rapidly responds to intestinal bacterial infection, also functions as a memory cell for long-term infection. In addition, ILC3 may monitor tissue and environmental damage, a function previously associated with T cells [87]. Intravital imaging shows that flagellin-induced ILC3 increases mobility, promotes IL-22 diffusion, and suppresses intestinal epithelial cell death. These ILC3 functions are regulated by T cells, the chemokine CCL25, and the microbiota, and are implicated in ILC3 patrolling [87]. Given their potent ability to induce antimicrobial defense and tissue-protective responses, tight regulatory mechanisms are required to prevent excessive or misdirected inflammation. Macrophages promote Treg differentiation by mediating retinoic acid signaling, producing IL-10, and inducing GM-CSF production by ILC3 in response to the microbiota [88]. In addition, ILC3s produce IL-2 in response to IL-1β stimulation, and this IL-2 has been reported to directly contribute to the maintenance of Treg cells (Fig. 2) [89]. Indeed, Ncr1ΔIL−2 mice exhibit a significant reduction in intestinal Treg cell numbers and increased susceptibility to inflammation [89]. Furthermore, exogenous IL-2 supplementation restores Treg cell numbers, demonstrating that ILC3-derived IL-2 directly supports Treg homeostasis [89]. In the mouse colon, FFAR2 (GPR43), expressed on ILC3, recognizes SCFAs produced by resident bacteria and activates AKT and STAT3, thereby inducing IL-22 production and ILC3 proliferation (Fig. 2) [90]. Furthermore, loss of ILC3-specific FFAR2 (FfarΔRorc) exacerbates C. rodentium- and DSS-induced colitis [90], indicating that metabolites produced by commensal bacteria play an important role in modulating ILC3 function and subsequent intestinal barrier function and homeostasis. Furthermore, this evidence suggests that ILC3 recognition of antigens is regulated not only indirectly through antigen-presenting cells but also directly through the sensing of microbiota-derived metabolites. By contrast, ILC3 stimulated by intestinal bacteria is regulated or suppressed by the host immune system. Intestinal epithelial cell-derived IL-25 and thymic stromal lymphopoietin (TSLP), a cytokine involved in mucosal immune regulation, negatively regulate ILC3, and loss of IL-25 (IL-25˗/˗) increases IL-22 expression [91, 92]. However, IL-25 regulation is indirect because the IL-25 receptor (IL-17RB) is not expressed on ILC3. Loss of TSLP (Tslp˗/˗ or neutralizing antibody treatment) protects against C. rodentium infection because TSLP suppresses IL-23-induced IL-22 production of ILC3 [92]. Receptor activator of nuclear factor kB ligand (RANKL), a tumor necrosis factor superfamily member, is also responsible for ILC3 inhibition [93]. The loss of RANKL in ILC3 (Tnfsf11ΔRORc) increases the abundance of CCR6+ ILC3 and the production of IL-17A and IL-22 during C. rodentium infection [93]. RANKL binds to RANK, which is expressed on the surface of ILC3, and ILC3s possess their own negative feedback system [93]. T cells also negatively regulate ILC3, and loss of T cells in mice (Rag1˗/˗ or Rag2˗/˗) strongly induces IL-22 production by ILC3, resulting in sustained STAT3 phosphorylation in intestinal epithelial cells [91, 94, 95]. Foxp3+ Treg suppresses ILC3-induced colitis by inhibiting IL-23 and IL-1b production by the intestinal resident CX3CR1 macrophages, thereby suppressing IL-22 production by ILC3 in a latent activation gene-3 (LAG-3) dependent manner [96]. Furthermore, IL-10 produced by CD4+ T cells also inhibits fucosylation of intestinal epithelial cells by ILC3 [97]. ILC3s have also been reported to induce immune tolerance. A recent report demonstrated that major histocompatibility complex class II (MHC II)-positive ILC3 suppresses inflammatory Th17 cells and induces the activation of microbiota-specific RORγt+ Treg cells [98]. The presence of MHC II+ ILC3 in the NCR˗ILC3 subset was identified through multi-omics analysis [99]. This regulation by MHC Ⅱ+ ILC3s is necessary for antigen presentation, αV integrin signaling, and competition for IL-2, which is inhibited at the onset of inflammatory bowel disease [98]. This report illustrates how the gut immune system provides tolerance to intestinal antigens, including resident bacteria. Collectively, these findings illustrate that microbiota-driven ILC3 activation is counterbalanced by multi-layered regulatory mechanisms. ILC3 activity is restrained both intrinsically, through cytokine and receptor-mediated negative feedback systems, and extrinsically, through T cell-dependent tolerance circuits. This dual regulatory architecture enables ILC3 to exert diverse functions—ranging from infection defense and tissue surveillance to immune tolerance—while maintaining intestinal homeostasis. The gut microbiota orchestrates crosstalk between innate and adaptive lymphocytes, thereby sustaining intestinal barrier integrity and immune homeostasis. Microbiota–ENS–ILC3 axis Emerging evidence indicates that the ENS plays a critical role in regulating ILC3 activity. ENS produces a variety of neuropeptides, among which vasoactive intestinal peptide (VIP) has been reported to be associated with ILC3 function (Fig. 2) [100–103]. VIP induced by feeding mediates VIP receptor 2 (VIPR2) expressed in ILC3 and suppresses IL-22 production, resulting in reduced RegIIIγ production and increased lipid transporter expression [100]. By contrast, loss of VIP (VIP˗/˗) has been reported to reduce intestinal IL-22 expression and IL-22-dependent Reg3γ and Fut2 expression, thereby increasing susceptibility to C. rodentium infection [101]. Another report showed that VIP stimulation of ILC3 isolated from the small intestine increases IL-22 production, and administration of exogenous VIP to mice increases IL-22-producing ILC3 [102]. Deletion of VIPR2 (VIPR2˗/˗) increased susceptibility to DSS-induced colitis [101]. In the context of IL-22 production, the apparent contradiction between VIP function and ILC3 function remains unresolved, suggesting the existence of a highly integrated ENS–ILC3 system. It has been reported that depletion of the ENS (vagotomy) reduces peritoneal ILC3 and delays the resolution of E. coli infection [103]. Furthermore, administration of acetylcholine to vagotomized mice enhances the defense against E. coli infection by activating ILC3 [103]. Subdiaphragmatic vagotomy reduces Fut2 expression and α1,2-fucosylation of intestinal epithelial cells [104]. This induction pathway has been shown to involve the pErk1/2-c-Fos axis, in which VIP produced by enteric neurons binds to VIPR1 on intestinal epithelial cells and plays a physiological role in defense against infection by E. faecalis [104]. Collectively, these findings indicate that ILC3s receive direct signals from the ENS and contribute to infection defense. In this context, ILC3s appear to integrate feeding-associated neural cues with microbiota-derived signals and dynamically modulate IL-22 production in a context-dependent manner, highlighting a novel physiological role of the ENS in reinforcing the intestinal barrier beyond nutrient absorption. Microbiota-dependent induction of IgA and IgA-mediated defense against enteric infection Induction of secretory IgA by the microbiota Secretory IgA (sIgA) is a key player in controlling gut microbes and defending against infection [105]. IgA has traditionally been recognized for its primary role in specifically neutralizing pathogenic microorganisms and toxins or preventing their colonization. However, recent studies have revealed that IgA does not merely eliminate pathogens but also suppresses their virulence factors and serves as a scaffold that supports the colonization of commensal bacteria. Here, we highlight the pathways underlying microbiota-driven IgA induction, the mechanisms by which distinct gut microbes promote IgA production, and the reciprocal regulation of the microbiota by IgA. The PPs are the site of IgA induction by the microbiota. In fact, intestinal IgA levels are drastically reduced in RORγt or lymphotoxin α (LTα)-deficient mice lacking PPs [106–109]. Importantly, the subepithelial dome region of the PPs initiates the IgA response, with the CCL20–CCR6 interaction recruiting B cells to the subepithelial dome region, resulting in interaction with subepithelial dome dendritic cells [109]. CCR6+ B cells further acquire antigen via direct contact with M cells, a pathway maintained even in the absence of classical CD11c+ MHC II+ dendritic cells, suggesting an independent antigen transport pathway of activation-induced cytidine deaminase and CXCR4 via the CD40 pathway [110–112]. Follicular helper T (Tfh) cells function as crucial helper cells in the induction of IgA+ B cells. Tfh cells are characterized by expression of CD4, CD40L, CXCR5, low levels of CD45, and the transcription factor BCL6, and are induced by IL-6 and IL-21, thereby mediating T cell-dependent B cell maturation through CD40–CD40L interactions [113, 114]. A recent study revealed that the T cell-independent pathway involves the transmembrane activator receptor TACI. Complete loss of IgA-producing plasma cells occurs in mice deficient in both T cells and TACI [115, 116]. Thus, the induction of IgA-producing plasma cells is not governed by a single pathway but is supported by redundant mechanisms, underscoring the central importance of IgA in host defense. IgA+ B cells ultimately migrate to the lamina propria of the small intestine and differentiate into plasma cells that produce IgA. IgA is secreted into the lumen through polymeric immunoglobulin receptor (plgR) on intestinal epithelial cells. Mice deficient in plgR exhibit reduced intestinal IgA levels but increased serum IgA, suggesting the existence of a mechanism for the selective secretion of sIgA locally within the mucosa [117]. Furthermore, serum IgA undergoes transcytosis via plgR on hepatocytes into the bile ducts and is subsequently excreted in bile [118]. Thus, a multi-layered regulatory system governs intestinal IgA production. IgA-inducing gut microbial species The IgA induction mechanisms described above are inseparable from the gut microbiota. The microbiota-driven induction of sIgA has long been established [119], with SFB serving as a prototypical example. Gnotobiotic mice colonized with SFB exhibit a marked expansion of IgA-producing plasma cells relative to mice colonized with E. coli, albeit with lower antigen specificity [120]. Other studies indicate that Bacteroides ovatus exhibits higher IgA production capacity than other Bacteroides species or E. coli, and that this induction is CD4+ T cell-dependent [121]. Interestingly, strains of B. ovatus exhibit both low and high IgA-induction capacities, suggesting strict IgA-induction control targeting specific factors in gut microbes and highlighting the importance of understanding strain-level variability [121]. Additionally, acetate, an SCFA metabolite produced by gut bacteria, activates IgA-producing plasma cells via GPR43 on dendritic cells [122]. Interestingly, acetate promotes T cell-dependent regulation of E. coli-specific IgA responses in the colon, suggesting that IgA production is tightly controlled by the combined actions of gut bacteria and their metabolites [123]. sIgA production has been reported not only by gut bacteria but also by fungi and protists. The gut-resident fungus C. albicans induces IgA-producing plasma cells and germinal center B cells in a T cell-dependent manner via dendritic cells and CX3CR1+ MNPs [124, 125]. The intestinal protozoan T. musculis increases germinal center B cells, Tfh, and ICOS+CD4+ non-Tfh in gut-associated lymphoid tissues, thereby inducing IgA-producing plasma cells [126]. Additionally, T. musculis not only induces strong IgA production following oral OVA administration but also elicits OVA-specific T cells in OT-II syngeneic experiments, suggesting it possesses natural adjuvant effects [126]. Other pathogens, such as rotavirus—a double-stranded RNA virus that infects intestinal epithelial cells—activate dendritic cells and B cells early in the PPs via oral administration, suggesting Myd88-mediated IgA production [127]. The gut microbiota not only participates in IgA induction but also in IgA specificity. In germ-free mice, common public B cell receptor clonotypes are present, and strong selection occurs even in the absence of the microbiota [128]. The presence of gut microbes increases the rate of change in B cell receptor clonotypes, suggesting that the germinal center not only possesses specific responsiveness to microbes but also mediates sustained adaptation to dietary molecules [128]. Taken together, sIgA is induced by a broad range of gut microorganisms while maintaining species-specific responsiveness. Thus, sIgA can be regarded as a tunable immune barrier that provides both flexibility and robustness in host–microbiota interactions. Interactions between IgA and the gut microbiota Commensal bacteria selectively promote IgA production by intestinal B cells, and microbiota-induced IgA safeguards the host by limiting inappropriate invasion of both commensal and pathogenic microbes, thereby preserving intestinal homeostasis. sIgA generated in response to commensal bacteria is predominantly polymeric and binds directly to bacteria [129]. IgA sequencing analysis provided evidence that IgA coats specific microbes, and IgA-coated bacteria are relatively immunocompetent pathobionts that cause inflammatory conditions in the gut [129]. For example, IgA promotes the agglutination of S. Typhimurium, preventing its proliferation, separation, and genetic transmissibility within the lumen [130]. IgA also binds to the agglutinin-like sequence family, which is expressed by highly pathogenic filamentous C. albicans, thereby inhibiting hyphal formation and reducing pathogenicity [124]. Intestinal IgA also prevents chronic colonization by mouse norovirus and astrovirus [131]. In addition, IgA induced by specific resident bacteria cross-reacts with the SARS-CoV-2 spike protein, suggesting that commensal bacteria create an IgA defense barrier against pathogens [132]. Recent reports indicate that the N-acetylmuramic acid-requiring gram-negative bacterium Tomasiella immunophila degrades intestinal IgA, increasing susceptibility to S. Typhimurium and C. albicans [133]. Additionally, T. immunophila was isolated from mice with low IgA levels and exhibits antibody-specific degradation, suggesting that IgA-degrading microorganisms also acquire functions through coevolution with their hosts [133]. Conversely, a symbiotic relationship between IgA and the gut microbiota has also been established. Bacteroides fragilis, possessing IgA-inducing capability, not only forms colonies in the colon as aggregates via its commensal colonization factors, but also enhances adhesion to the epithelium by increasing specific IgA through commensal colonization factors [134]. This suggests that IgA serves as a scaffold for B. fragilis colonization. Bacteroides thetaiotaomicron, a human commensal bacterium, possesses polysaccharide utilization loci for using dietary fructans, and it has been demonstrated that IgA downregulates the expression of these genes by targeting polysaccharide utilization loci, thereby controlling microbial metabolism [135]. Thus, IgA exhibits a dual role in excluding pathogens while supporting commensal bacteria, indicating that IgA and the gut microbiota have undergone coevolutionary adaptation. Conclusions In this review, we summarize the mechanisms by which resident microbes stimulate host epithelial and immune responses and prevent colonization and infection by enteric pathogens, as well as the development of inflammatory diseases. Specific commensal bacteria prevent colonization and infection by pathogenic microorganisms by regulating the differentiation and proliferation of host immune cells, particularly innate and adaptive lymphocytes. However, the intestinal microbiota forms a highly complex ecosystem based not only on microbial interactions but also on host–microbe interactions. In the context of preventive or therapeutic approaches for infectious diseases, accumulating evidence indicates that fecal microbiota transplantation is effective in protecting against pathogenic bacterial infections. However, concerns have been raised that donor fecal material may harbor not only microbiota that confer protective effects against infection but also undesired pathogenic microorganisms and potentially harmful components. Accordingly, recent efforts worldwide have focused on developing microbiome-based therapeutics composed of defined consortia of beneficial gut bacteria, isolated and formulated as cocktails. However, to fully understand the protective effects of commensal bacteria against pathogenic infections and inflammatory diseases, it is essential to establish an intestinal niche that permits their stable colonization, expansion, and sustained production of metabolites that suppress or eliminate pathogenic microbes and inflammation. Multiple factors, including host genetic background, dietary nutrients, and epithelial and immune responses, shape the composition and function of the gut microbiota. A deeper understanding of the factors that shape the gut microbiota and the mechanisms underlying host–microbe interplay is expected to facilitate the development of more effective microbiota-targeted therapies for infectious and inflammatory diseases. Acknowledgements We thank Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript. Author contributions D.M. Y.G.: Writing-Original draft, M.D.: Visualization, Y.G.: Writing-review & editing, Y.G.: Supervision, Y.G.: Funding acquisition. Funding The present research was funded by the AMED (Grant number: JP223fa627003), JSPS KAKENHI (Grant numbers: 24H00550, 25K02491), JST FOREST Program (Grant number: JPMJFR225D), and the Yakult Bio-Science Foundation. Data availability Data sharing is not applicable to this article as no new data were created. Declarations Ethics declarations Not applicable. Conflict of interest The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no new data were created.